Elutia Inc. (NASDAQ: ELUT) Reducing Surgical Infection Risk & Scaling Commercial Adoption

Why It Matters

Elutia’s proven antibiotic‑biomaterial platform could dramatically reduce infection complications in a high‑volume surgery, unlocking a multi‑billion‑dollar market and delivering strong upside for shareholders.

Key Takeaways

• Elutia targets 20% infection rate in breast reconstruction surgeries.
• Uses antibiotic‑laden biomaterials proven successfully in pacemaker market.
• Prior product generated $18M in nine months, sold for $88M.
• NXT‑41X FDA approval expected 2027; 192 hospitals already contracted.
• Strong balance sheet $44M cash, no debt, supports rapid rollout.

Summary

Elutia Inc. (NASDAQ: ELUT) is positioning its antibiotic‑infused biomaterial platform to slash the roughly 20% post‑operative infection rate that plagues breast reconstruction after mastectomy. The company highlighted its upcoming NXT‑41X product, which integrates a sustained‑release antibiotic payload into standard surgical materials, and announced a planned FDA filing for the first half of 2027.

The technology is not theoretical; Elutia’s predecessor, LU‑Pro, tackled infections in pacemaker implants, achieving $18 million in sales within nine months and culminating in an $88 million acquisition by Boston Scientific. That track record, combined with a $44 million cash reserve and zero debt, underpins confidence that the larger breast‑reconstruction market—over 162,000 annual procedures—offers blockbuster potential.

CEO Randy Mills emphasized rapid clinical uptake: within nine months, the product secured contracts with 192 hospitals and earned uniform surgeon adoption because it adds no procedural steps or extra costs. He also noted the team’s deep experience, with an average tenure of 6.3 years, and two pending business‑development deals expected to further bolster capital.

If FDA clearance arrives as projected, Elutia could capture a sizable share of a $1.5 billion U.S. market, delivering a clear value proposition to surgeons, hospitals, and patients while providing investors with a high‑growth, low‑debt opportunity.

Original Description

In this interview, Randy Mills, President and CEO of Elutia Inc. (NASDAQ: ELUT), discusses the company's innovative approach to reducing post-operative infections in breast reconstruction surgery using biologically based materials with antibiotic payloads. He shares insights into the company's history, technology, market potential, recent commercial success, and upcoming catalysts.

Chapters

00:00 Introduction to Elutia Inc.

01:58 The Impact of Breast Cancer

04:36 Unique Solutions for Postoperative Infections

07:27 Commercial Uptake and Future Prospects

09:43 Randy Mills' Background and Key Catalysts

Elutia Inc. will be presenting at the upcoming Planet MicroCap Las Vegas 2026 powered by MicroCapClub. Register to attend here: https://www.meetmax.com/sched/event_130817/conference_home.html

For more information about Elutia Inc., please visit: https://elutia.com/

The interview may contain forward looking statements about Elutia Inc. See Elutia Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.

About Elutia Inc.

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Planet Microcap hosts the highest quality in-person microcap events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow.; visit https://planetmicrocap.com/ to learn more about our Las Vegas and Toronto events.

This presentation is for informational purposes only and should not be construed as a recommendation to purchase or sell any security referenced herein. Planet MicroCap Holdings LLC and MicroCapClub LLC (collectively, “we” or “our”) are not licensed brokers nor registered investment advisors. We, our partners, contractors, members, subscribers, guests, or affiliates may or may not hold positions in one or more of the securities mentioned in this presentation and may trade in such securities at any time. We may have received cash compensation from one or more participants for presenting at past, present, or future events. We recommend you consult a licensed investment adviser, broker, or legal counsel before purchasing or selling any securities referenced in this presentation.